Description
EXERCISE TWO MONTHS OF OPTION YEAR TWO
Base award description: BPA FOR SODIUM OXYBATE
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2023-10-17+$0= $0
- Mod P000012024-04-10+$0= $0
- Mod P000022024-09-30+$0= $0
- Mod P000032024-12-09+$0= $0
- Mod P000042025-10-15+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2023-10-17 | +$0 | $0 | BPA FOR SODIUM OXYBATE |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-04-10 | +$0 | $0 | SODIUM OXYBATE PRICE CHANGE |
| Mod P00002· EXERCISE AN OPTION | 2024-09-30 | +$0 | $0 | EXERCISE OPTION YEAR 1 |
| Mod P00003· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-12-09 | +$0 | $0 | 2025 PUBLIC LAW UPDATES |
| Mod P00004· EXERCISE AN OPTION | 2025-10-15 | +$0 | $0 | EXERCISE TWO MONTHS OF OPTION YEAR TWO |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI LVEBAQTPN615)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79726A0013 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C26026F0059 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $319,399 | FY2026 |
| 36C26025F0044 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $173,089 | FY2025 |
| 36C26024F0050 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $185,400 | FY2024 |
| 36F79722D0161 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79719N0017 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $100,295 | FY2019 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79724A0001_3600 · retrieved 2026-09-26.